Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 13 clinical trials
Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal Cancer

In this context, the assessment of RAS (N- and K-) oncogene mutations is able to predict the response to anti-EGFR agents being mutated RAS mCRC patients resistant to these drugs. In this group of patients the use of anti-angiogenic drugs (bevacizumab and aflibercept) is predominant.

metastatic colorectal cancer
aflibercept
oxaliplatin
vegf
vascular endothelial growth factor
  • 0 views
  • 19 Feb, 2024
Optimal EGFR TKIs Treatment Strategies for Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion Variants

To determine the optimal EGFR TKIs treatment strategies for lung adenocarcinoma harboring EGFR exon 19 deletion variants

  • 0 views
  • 19 Feb, 2024
A Clinical Study of Pyrotinib in Patients of Advanced Colorectal Cancer With Her2 Variation

To Observe the Efficacy and Safety of Pyrotinib Maleate in Patients With Advanced HER2 Variation Colorectal Cancer

erbb2
metastasis
liver metastasis
her-2
immunohistochemistry
  • 0 views
  • 19 Feb, 2024